Copyright © 2001 by the European Society of Cardiology.
Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene
Department of Internal Medicine IV, Division of Cardiology, University of Frankfurt, Germany
revised June 10, 2000; accepted June 21, 2000
Abstract
Aims Platelets play a central role in the restenosis process by inducing neointimal proliferation after coronary interventions. Glycoprotein IIb/IIIa PlA2polymorphism has been associated with the occurrence of acute coronary syndromes and increased restenosis rates. Statins have been shown to exert potent antiproliferative, antiinflammatory and antithrombotic properties, thereby potentially interfering with the major processes of in-stent restenosis. Therefore, we sought to find out whether statin therapy interferes with restenosis and clinical outcome at 6 months following successful coronary stent implantation in the presence or absence of the PlA2allele.
Methods and Results Six hundred and fifty consecutive patients were followed for 6 months after coronary stent insertion. Carriers of the PlA2allele demonstrated a significantly increased restenosis rate, which was abrogated by statin therapy (50·9% vs 28·6%, P=0·01). Moreover, statin therapy was associated with a significant reduction (28·2% vs 49·3%,P <0·01) in the occurrence of major adverse coronary events (myocardial infarction, cardiac death, target vessel revascularization) in the 6 months after the intervention in patients with the PlA2allele.
Conclusion Statin therapy reduces increased stent restenosis rates and improves clinical outcome following coronary stent implantation in patients bearing the PlA2allele, suggesting that statins interfere with the functional consequence of a genetically determined platelet-mediated risk factor associated with PlA2polymorphism.
Key Words: Stents, restenosis, platelets, glycoproteins, statin
f1 Correspondence: Andreas M. Zeiher, MD, Department of Internal Medicine IV, Division of Cardiology, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. K.J. Oksala, M. Heikkinen, J. Mikkelsson, T. Pohjasvaara, M. Kaste, T. Erkinjuntti, and P. J. Karhunen Smoking and the Platelet Fibrinogen Receptor Glycoprotein IIb/IIIA PlA1/A2 Polymorphism Interact in the Risk of Lacunar Stroke and Midterm Survival Stroke, January 1, 2007; 38(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lerman Restenosis: Another "Dysfunction" of the Endothelium Circulation, January 4, 2005; 111(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Bae, E. Bassenge, K.-Y. Kim, Y.-C. Synn, k.-R. Park, and M. Schwemmer Effects of Low-Dose Atorvastatin on Vascular Responses in Patients Undergoing Percutaneous Coronary Intervention With Stenting Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 185 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Schomig, J. Mehilli, H. Holle, K. Hosl, D. Kastrati, J.u. Pache, M. Seyfarth, F.-J. Neumann, J. Dirschinger, and A. Kastrati Statin treatment following coronary artery stenting and one-year survival J. Am. Coll. Cardiol., September 4, 2002; 40(5): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Kandzari and P. J. Goldschmidt-Clermont Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1028 - 1032. [Full Text] [PDF]
|
|
|
|
|
|
A. Kastrati and A. Schomig Good medicines for bad genes Eur. Heart J., April 1, 2001; 22(7): 523 - 525. [PDF]
|
|